Clinical Trials Logo

Filter by:
NCT ID: NCT06449729 Completed - Hypoparathyroidism Clinical Trials

Endocrine Determinants of Renal Function in Patients With Hypoparathyroidism

ENDORSE
Start date: November 28, 2022
Phase:
Study type: Observational

Endocrine determinants of renal function in patients with hypoparathyroidism on conventional treatment: a cross-sectional study (ENDORSE)

NCT ID: NCT06449651 Recruiting - Clinical trials for Thrombocytopenia, Neonatal Alloimmune

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

FREESIA-1
Start date: June 25, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

NCT ID: NCT06449495 Recruiting - Clinical trials for Coordination and Balance Disturbances

Virtual Reality for Pediatric Motor Rehabilitation.

Start date: September 1, 2012
Phase: N/A
Study type: Interventional

Balance and coordination disorders limit the achievement of autonomy in movement and activities of daily living in pediatric population. There are several systems that can be used to treat balance and coordination disorders and those that use virtual reality, such as NIRVANA, are becoming increasingly popular. The primary objective of this post-market clinical investigation is to evaluate the efficacy of the semi-immersive virtual reality platform NIRVANA (BTS Bioengineering), in accordance with the protocol defined at IRCCS Medea in Bosisio Parini, in children with balance and coordination disorders on both motor function and cognitive processes that are indirectly stimulated.

NCT ID: NCT06449248 Completed - Oral Lichen Planus Clinical Trials

Oral Lichen Planus and Systemical Oncological Comorbidities

Start date: January 2, 2023
Phase:
Study type: Observational

Lichen planus (LP) is a chronic mucocutaneous inflammatory disease of unknown etiology. In its oral variant, oral lichen planus (OLP) has a reported prevalence ranging from 0.5% to 2.2% in the general population. The disease typically occurs between the ages of 30 and 60. Although the pathogenetic mechanism and the triggering factor remain unknown, an immune-mediated pathogenesis and the role of factors such as stress, anxiety, diabetes, other autoimmune diseases, hypertension, intestinal pathologies, chronic liver diseases, hypercholesterolemia, infections have been hypothesized , contact with dental materials, tumors and genetic predisposition to cancer. Oral lichen planus is one of the potentially malignant disorders, showing a malignant transformation rate of 1.4%. A preliminary analysis conducted in our research center has shown a correlation between OLP and systemic tumors, both solid and haematological, involving areas not involved in lesions attributable to OLP. According to these data, the objective of the study is to evaluate whether there is an association between OLP and peripheral tumors, both solid and haematological. The primary objective will be to investigate the possible existence of a statistically significant association between OLP and the development of systemic oncological pathologies. Secondary objective will be to investigate the existence of an association between the various forms of OLP and specific oncological pathologies and to evaluate whether the presence of other systemic pathologies and lifestyle factors (diabetes, hypertension, chronic liver disease, smoking, alcohol, infection by HPV, HCV, etc ...) could influence such association (primary outcome). The objectives will be pursued through the analysis of data collected from the medical records of patients belonging to the General Dentistry and Orthodontic Outpatient Clinics at the "Agostino Gemelli" Teaching Hospital and in the Oral Pathology Outpatient Clinics of the other centers involved.

NCT ID: NCT06448988 Not yet recruiting - Clinical trials for Ventilator-Induced Lung Injury

Evaluation of Respiratory Mechanics in Supine and PARK-bench Positions (SPARK)

SPARK
Start date: July 1, 2024
Phase:
Study type: Observational

The primary objective of this prospective observational physiological study is to evaluate the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.

NCT ID: NCT06448936 Not yet recruiting - Clinical trials for Basal Cell Carcinoma

Quality of Life in Patients With Difficult-to-treat Basal Cell Carcinoma

FACE-QOL
Start date: June 3, 2024
Phase:
Study type: Observational

FACE-QoL is an observational, prospective, multicenter study to evaluate the impact of surgical treatment on Quality of Life in patients with stage IIA and IIIB difficult-to-treat basal cell carcinoma of the face, according to the European Academy of Dermato Oncology classification, using Patient Reported Outcomes. The main questions it aims to answer are: - Surgery, as a gold standard for treatment, can lead to an improvement in patients' quality of life in difficult-to-treat basal cell carcinoma in functionally and cosmetically challenging sites of the face (i.e., stage IIA and IIIB) - Identify which clinical and individual variables have the greatest impact on patients' quality of life. Participants will answer questionnaires about quality of life and the impact of the disease on their lives.

NCT ID: NCT06448819 Completed - Crohn Disease Clinical Trials

Real-life Use of the Crohn's Disease Exclusion Diet (CDED) in Adult Patients With Crohn's Disease

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

This study explores the effectiveness od the Crohn's Disease Exclusion Diet (CDED) as a tretament for adults with mild-to-moderate Crohn's disease (CD). The hypotesis is that CDED, by excluding specific dietary components thought to exacerbate gut inflammation, can induce remission in CD patients more effectively than a control diet based on the Mediterranean pattern. Conducted as an open-label randomized trial, the research aim to provide real-world evidence of CDED's safety and its inpact on clinical remission, body composition and overall quality of life for CD patients.

NCT ID: NCT06448663 Recruiting - CDKL5 Clinical Trials

Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)

NUTRIENT
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Standard anti-seizure medications have limited efficacy in seizure control in cyclin-dependent kinase-like 5 deficiency disorder (CDD). The study will investigate whether targeting the gut-microbiota-brain axis in CDD patients can alleviate seizures and ameliorate other comorbidities.

NCT ID: NCT06448325 Recruiting - Osteoporosis Risk Clinical Trials

Fragility Re-fractures Prediction Score

RIFRA
Start date: May 28, 2024
Phase:
Study type: Observational

Fragility fractures increase among elderly patients worldwide, representing a global burden in terms of disability and care expenditure. Osteoporosis is asymptomatic up to the moment in which a first fracture occurs, reason why it is often underdiagnosed. Even after that, further fractures do occurr, as osteoporosis is often untreated. Several programs have been introduced worldwide to prevent secondary fractures among the population at risk (e.g., International Osteoporosis Foundation's Capture the Fracture), and several risk factors are being investigated to generate a predictive score. However, accurate validation is needed to make these scores reliable. In this retrospective observational study, we aim to validate a predictive score trained on a population of elderly patients with a cohort of patients who underwent hip fracture surgery in a high-volume orthopedic center in the Region of Lombardy.

NCT ID: NCT06447935 Completed - Myocarditis Clinical Trials

Acute Eosinophilic Myocarditis International Registry

Start date: November 16, 2021
Phase:
Study type: Observational

Retrospective collection of clinical, histological, imaging data regarding patients with acute histologically-proven eosinophilic myocarditis.